DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Development and Piloting an Avatar-based Intervention to Support Patients Undergoing Stem Cell Transplantation

Not Applicable

Completed

Conditions: Hematopoietic Cell Transplantation

Interventions: Behavioral: Care.Coach

First Posted Date: 2022-10-31

Last Posted Date: 2024-07-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 18

Registration Number: NCT05600101

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Investigating Hereditary Risk In Thoracic Cancers (INHERIT)

Recruiting

Conditions: Lung Cancer
Genetic Predisposition
Hereditary Diseases
Genetic Disease

Interventions: Genetic: Data and Specimen Collection

First Posted Date: 2022-10-20

Last Posted Date: 2025-03-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 500

Registration Number: NCT05587439

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

UNTIRE: Cancer-related Fatigue With Digital Treatment

Not Applicable

Withdrawn

Conditions: Colorectal Cancer
Fatigue

Interventions: Behavioral: UNTIRE App

First Posted Date: 2022-10-18

Last Posted Date: 2025-03-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT05584540

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

PROFAST Intervention in Precursor Multiple Myeloma

Not Applicable

Recruiting

Conditions: MGUS
Smoldering Waldenstrom Macroglobulinemia(WM)
Multiple Myeloma
Weight Loss
Cancer Prevention
Fasting

Interventions: Behavioral: Prolonged Fasting Intervention
Behavioral: EDUCATION CONTROL

First Posted Date: 2022-10-04

Last Posted Date: 2025-04-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT05565638

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Drug Screening Using Novel IMD in ACC and Salivary Cancers

Early Phase 1

Not yet recruiting

Conditions: Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma of the Salivary Gland

Interventions: Combination Product: Implantable Microdevice (IMD)

First Posted Date: 2022-09-23

Last Posted Date: 2022-09-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT05553782

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients

Not Applicable

Recruiting

Conditions: Breast Cancer
Breast Cancer Female
Stage III Breast Cancer
Stage I Breast Cancer
Stage II Breast Cancer

Interventions: Behavioral: THRIVE
Behavioral: Health Education Support Program

First Posted Date: 2022-09-10

Last Posted Date: 2025-04-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 270

Registration Number: NCT05535192

Locations: 🇺🇸
Case Western Reserve University/University Hospitals Cleveland, Cleveland, Ohio, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)

Not Applicable

Active, not recruiting

Conditions: Chemotherapy-induced Peripheral Neuropathy
Acupuncture
Early-stage Breast Cancer
Breast Cancer Stage I
Breast Cancer Stage II
Breast Cancer Stage III

Interventions: Device: Acupuncture
Other: Nature scenery with a relaxation exercise

First Posted Date: 2022-09-06

Last Posted Date: 2025-05-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 89

Registration Number: NCT05528263

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

The SPOT-HPV Study

Active, not recruiting

Conditions: HPV Infection
HPV Positive Oropharyngeal Squamous Cell Carcinoma

Interventions: Diagnostic Test: Salivary TTMV-HPV DNA Test
Diagnostic Test: Blood TTMV-HPV DNA Test

First Posted Date: 2022-09-01

Last Posted Date: 2024-04-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 360

Registration Number: NCT05524025

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham & Woman's Hospital, Boston, Massachusetts, United States

Cardiotoxicities in Patients Receiving BTKi

Withdrawn

Conditions: Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia

Interventions: Diagnostic Test: Electrocardiogram
Diagnostic Test: Echocardiogram
Diagnostic Test: Cardiac magnetic resonance imaging
Device: Mobile cardiac telemetry
Diagnostic Test: Blood pressure monitoring
Diagnostic Test: Blood draw

First Posted Date: 2022-08-30

Last Posted Date: 2024-10-15

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT05521178

Sleep Treatment Education Program-1 (STEP-1)

Not Applicable

Completed

Conditions: Insomnia
Cancer Survivors

Interventions: Behavioral: Sleep Treatment Education Program (STEP-1)
Behavioral: Enhanced Usual Care

First Posted Date: 2022-08-29

Last Posted Date: 2024-10-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 70

Registration Number: NCT05519982

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy